{"entity":{"id":"paper-srinivasan-sq3370-injected-and-non-injected-lesions-adv-ther-2021","kind":"paper","name":"SQ3370 in mice with two tumours: responses in the injected and the non-injected lesion","aka":["SQ3370 Activates Cytotoxic Drug via Click Chemistry at Tumor and Elicits Sustained Responses in Injected and Non-Injected Lesions"],"tldr":"A mouse study from Shasqi. The biopolymer was injected into one of two tumours and the doxorubicin prodrug given into the blood; both tumours responded and the mice lived longer.","summary":"A preclinical study of SQ3370 in mice bearing two tumours, of which only one was injected with the biopolymer before systemic doses of the attenuated doxorubicin prodrug. SQ3370 was well tolerated at 5.9 times the maximum dose of conventional doxorubicin, increased survival by 63 per cent and produced an anti-tumour response against both the injected and the non-injected lesion. The sustained response correlated with immune activation measured at both lesions, and the authors suggest the approach could help patients with micro-metastatic disease.","asOf":"2026-11-16","links":[{"label":"Adv Ther 2021","url":"https://doi.org/10.1002/adtp.202000243"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/33869738/"},{"label":"Europe PMC (free full text)","url":"https://europepmc.org/article/MED/33869738"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["click-activated-prodrugs"],"targets":[],"drugs":["sq3370"],"companies":["shasqi"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo (company site, ClinicalTrials.gov v2, Crossref, Europe PMC, NIH RePORTER)","editedOn":"2026-11-16"},"journal":"Advanced Therapeutics","year":2021,"doi":"10.1002/adtp.202000243","pmid":"33869738","authors":"Srinivasan S, Yee NA, Wu K, et al.","paperType":"translational","findings":["Well tolerated in mice at 5.9 times the maximum dose of conventional doxorubicin.","Survival increased by 63 per cent.","Anti-tumour response against injected and non-injected lesions, correlated with immune activation at both."],"whatItMeans":"This is the animal evidence behind the hope that treating one injectable tumour could help disease elsewhere. In the human trial that followed, shrinkage of non-injected lesions was seen, but the overall response rate was no higher than with standard doxorubicin.","caveats":["Mouse models only. Figures are from the abstract; the comparison group for the survival figure is not stated there.","Led by Shasqi authors."],"changedPractice":false},"route":"/key-papers/paper-srinivasan-sq3370-injected-and-non-injected-lesions-adv-ther-2021/","neighbours":{"technology":[{"id":"click-activated-prodrugs","kind":"technology","name":"Click-activated prodrugs (bioorthogonal drug activation in the body)","route":"/technologies/click-activated-prodrugs/"}],"drug":[{"id":"sq3370","kind":"drug","name":"SQ3370","route":"/drugs/sq3370/"}],"company":[{"id":"shasqi","kind":"company","name":"Shasqi","route":"/companies/shasqi/"}]}}